
Eberhard Gunsilius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7816316/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemiaâ€variant. Genes Chromosomes and Cancer, 2021, 60, 287-292.	1.5	8

Reduced alpha diversity of the oral microbiome correlates with short progressionâ€free survival in 2 patients with relapsed/refractory multiple myeloma treated with ixazomibâ€based therapy (AGMT MM 1,) Tj ETQq00040 rgBT Øverlock 1

3	Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. Blood Advances, 2021, 5, 1746-1754.	2.5	10
4	Symmetric bilateral liposarcoma in an interventional cardiologist. Lancet Oncology, The, 2021, 22, e173.	5.1	0
5	Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis. Memo - Magazine of European Medical Oncology, 2021, 14, 287-291.	0.3	1
6	Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Blood Advances, 2021, 5, 3515-3527.	2.5	6
7	Multiple myeloma: my highlights at ASH 2020. Memo - Magazine of European Medical Oncology, 2021, 14, 231-234.	0.3	1
8	Interesting news from the annual meeting of the American Society of Hematology 2020. Memo - Magazine of European Medical Oncology, 2021, 14, 215-215.	0.3	0
9	Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report. Case Reports in Oncology, 2021, 14, 1337-1341.	0.3	1
10	Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. Journal of Nephrology, 2021, 34, 1263-1270.	0.9	3
11	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leukemia and Lymphoma, 2020, 61, 377-386.	0.6	14
12	Creating the "new normal―post-Coronavirus world—web-communication replacing face-to-face interaction. Memo - Magazine of European Medical Oncology, 2020, 13, 245-246.	0.3	2
13	News from ASH 2019. Memo - Magazine of European Medical Oncology, 2020, 13, 247-248.	0.3	0
14	The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. American Journal of Hematology, 2020, 95, 1562-1571.	2.0	20
15	The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. Cancers, 2020, 12, 2341.	1.7	4
16	Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report. Journal of Clinical Apheresis, 2020, 35, 227-230.	0.7	2
17	Circumnavigating the challenges of COVID-19 in oncology. Memo - Magazine of European Medical Oncology, 2020, 13, 135-138.	0.3	2
18	CAR-T cells in multiple myeloma: current status. Memo - Magazine of European Medical Oncology, 2020, 13, 43-49.	0.3	4

#	Article	IF	CITATIONS
19	Multiple cerebral lesions in a patient with refractory celiac disease: A case report. World Journal of Gastroenterology, 2020, 26, 7584-7592.	1.4	2
20	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). Blood, 2020, 136, 27-29.	0.6	0
21	Immunosuppression and its complications. Memo - Magazine of European Medical Oncology, 2019, 12, 191-191.	0.3	1
22	Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 2019, 121, 751-757.	2.9	17
23	Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. International Journal of Medical Sciences, 2019, 16, 115-124.	1.1	5
24	Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78. Frontiers in Oncology, 2019, 9, 1530.	1.3	20
	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq1	0.784314	rgBT /Overloc
25	Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02), Blood, 2019, 134, 696-696.	0.6	4
26	Cytotoxics and Anti-angiogenics: Metronomic Therapies. , 2019, , 327-347.		0
27	Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. Oncology Research and Treatment, 2018, 41, 188-193.	0.8	35
28	The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research, 2018, 38, 5087-5092.	0.5	6
29	FOXF1 Mediates Endothelial Progenitor Functions and Regulates Vascular Sprouting. Frontiers in Bioengineering and Biotechnology, 2018, 6, 76.	2.0	14
30	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PLoS ONE, 2018, 13, e0202045.	1.1	40
31	Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget, 2018, 9, 2344-2356.	0.8	53
32	Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1. Blood, 2018, 132, 3275-3275.	0.6	0
33	Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e75.	0.2	1
34	memo: Spectacular developments during the last decade from the Section Editors' point of view. Memo - Magazine of European Medical Oncology, 2017, 10, 4-7.	0.3	0
35	High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS ONE, 2017, 12, e0181487.	1.1	10
36	Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?. Oncotarget, 2017, 8, 5081-5091.	0.8	14

#	Article	IF	CITATIONS
37	Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget, 2017, 8, 56243-56254.	0.8	15
38	Cytotoxics and Anti-Angiogenics: Metronomic Therapies. , 2017, , 1-22.		0
39	Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial. Blood, 2016, 128, 3335-3335.	0.6	3
40	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget, 2016, 7, 78605-78618.	0.8	6
41	Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. Oncotarget, 2016, 7, 20109-20123.	0.8	14
42	Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol. Blood, 2016, 128, 5692-5692.	0.6	0
43	Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis. Journal of Visualized Experiments, 2015, , e52665.	0.2	15
44	The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo. BMC Cancer, 2015, 15, 738.	1.1	14
45	Lymphoma: anything new?. Memo - Magazine of European Medical Oncology, 2015, 8, 3-4.	0.3	Ο
46	Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia. Wiener Klinische Wochenschrift, 2015, 127, 631-634.	1.0	3
47	Marine compounds inhibit growth of multiple myeloma <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2015, 6, 8200-8209.	0.8	6
48	Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone. Anticancer Research, 2015, 35, 2165-8.	0.5	6
49	Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets. Memo - Magazine of European Medical Oncology, 2014, 7, 202-205.	0.3	2
50	New Antiangiogenic Strategies beyond Inhibition of Vascular Endothelial Growth Factor with Special Focus on Axon Guidance Molecules. Oncology, 2014, 86, 46-52.	0.9	18
51	SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocrine-Related Cancer, 2014, 21, 175-187.	1.6	34
52	Polyarteritis nodosa complicating multiple myeloma – a case report and review of the literature. , 2014, 33, 143-157.		3
53	A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Anticancer Research, 2014, 34, 2559-64.	0.5	6
54	"ldiopathic Bence-Jones proteinuriaâ€ŧ a new characterization of an old entity. Annals of Hematology, 2013, 92, 1263-1270.	0.8	7

#	Article	IF	CITATIONS
55	The Liver Graft as Trojan Horse–Multilineage Donor-Derived Hematopoiesis After Liver Transplantation: Case Report. Transplantation Proceedings, 2013, 45, 3438-3441.	0.3	5
56	Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient. Memo - Magazine of European Medical Oncology, 2012, 5, 27-29.	0.3	1
57	Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2011, 105, 72-80.	1.8	14
58	Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma. Strahlentherapie Und Onkologie, 2011, 187, 300-305.	1.0	6
59	Multiple myeloma at ASH 2010: Some points that might change our daily practice. Memo - Magazine of European Medical Oncology, 2011, 4, 115-116.	0.3	1
60	Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 635-646.	1.4	16
61	Bortezomib for the treatment of refractory Typeâ€l cryoglobulinaemia. British Journal of Haematology, 2010, 150, 235-237.	1.2	15
62	Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study. Blood, 2010, 116, 1380-1380.	0.6	1
63	Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer, 2009, 9, 284.	1.1	27
64	Obscure gastrointestinal bleeding. Memo - Magazine of European Medical Oncology, 2009, 2, 154-159.	0.3	0
65	Lymphoproliferative diseases. Memo - Magazine of European Medical Oncology, 2009, 2, 127-127.	0.3	0
66	Hodgkin lymphoma in Tyrol—a population-based study. Annals of Hematology, 2009, 88, 449-456.	0.8	5
67	Adenoviral-Mediated Endothelial Precursor Cell Delivery of Soluble CD115 Suppresses Human Prostate Cancer Xenograft Growth in Mice. Stem Cells, 2009, 27, 2342-2352.	1.4	16
68	GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood, 2009, 114, 3960-3967.	0.6	121
69	The Dickkopfâ€homolog 3 is expressed in tumor endothelial cells and supports capillary formation. International Journal of Cancer, 2008, 122, 1539-1547.	2.3	63
70	Visions have been realised. Memo - Magazine of European Medical Oncology, 2008, 1, 1-1.	0.3	0
71	Are adjuvant therapies beyond all doubt?. Memo - Magazine of European Medical Oncology, 2008, 1, 53-53.	0.3	0
72	Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International Journal of Hematology, 2008, 88, 508-515.	0.7	94

#	Article	IF	CITATIONS
73	Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. International Journal of Hematology, 2008, 87, 382-386.	0.7	2
74	Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. BMC Research Notes, 2008, 1, 71.	0.6	30
75	Alternative Splicing of Vasohibin-1 Generates an Inhibitor of Endothelial Cell Proliferation, Migration, and Capillary Tube Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 478-484.	1.1	37
76	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: A methodological challenge and an ongoing debate on the clinical relevance. Oncology Reports, 2008, , .	1.2	8
77	Dickkopf-3 As a New Potential Marker for Neoangiogenesis in Colorectal Cancer: Expression in Cancer Tissue and Adjacent Non-Cancerous Tissue. Disease Markers, 2008, 24, 101-109.	0.6	38
78	Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study. Blood, 2008, 112, 3175-3175.	0.6	17
79	Targeting human solid tumor xenografts with ex vivo expanded endothelial progenitor cells. FASEB Journal, 2008, 22, 901.4.	0.2	Ο
80	Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma. Blood, 2008, 112, 3317-3317.	0.6	0
81	Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respiratory Research, 2007, 8, 50.	1.4	88
82	Molecular therapies for malignant glioma. Wiener Medizinische Wochenschrift, 2006, 156, 351-363.	0.5	21
83	Marginal zone lymphoma of the lacrimal gland spreading to the lung and the bone marrow 11Âyears after first symptoms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 361-365.	1.4	2
84	Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients. Cancer Immunology, Immunotherapy, 2006, 55, 1198-1208.	2.0	29
85	CD34+/CD133â^' circulating endothelial precursor cells (CEP): Characterization, senescence and in vivo application. Experimental Gerontology, 2006, 41, 600-608.	1.2	32
86	RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Experimental Hematology, 2005, 33, 767-775.	0.2	68
87	Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents. Journal of the National Cancer Institute, 2005, 97, 540-541.	3.0	10
88	Response. Circulation, 2005, 111, e307-e308.	1.6	1
89	The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer. Clinical Cancer Research, 2005, 11, 8326-8331.	3.2	474
90	CD4+CD25+ Regulatory T Cells Inhibit Experimental Anti-Glomerular Basement Membrane Glomerulonephritis in Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 1360-1370.	3.0	168

#	Article	IF	CITATIONS
91	Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Human Pathology, 2005, 36, 1148-1151.	1.1	34
92	Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1 Blood, 2005, 106, 4467-4467.	0.6	0
93	Maintenance of Telomere Length in Peripheral Blood CD4+CD25+ Regulatory T-Cells of Cancer Patients Despite Active Proliferation Blood, 2005, 106, 3309-3309.	0.6	0
94	Diagnosing Invasive Aspergillosis during Antifungal Therapy by PCR Analysis of Blood Samples. Journal of Clinical Microbiology, 2004, 42, 4154-4157.	1.8	107
95	Disseminated Infection with Prototheca zopfii after Unrelated Stem Cell Transplantation for Leukemia. Journal of Clinical Microbiology, 2004, 42, 4907-4908.	1.8	48
96	Endothelial progenitor cells: A source for therapeutic vasculogenesis?. Journal of Cellular and Molecular Medicine, 2004, 8, 509-518.	1.6	74
97	Telomerase Activity and Telomere Length of CD4+CD25+ Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion Blood, 2004, 104, 3857-3857.	0.6	0
98	Stable RNAi-Mediated Knock-Down of P-Glycoprotein by a Transposon-Based Vector System Restores Imatinib Sensitivity Blood, 2004, 104, 2090-2090.	0.6	0
99	Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Annals of Hematology, 2003, 82, 621-627.	0.8	24
100	Hematopoietic stem cells in chronic myeloid leukemia. Archives of Medical Research, 2003, 34, 496-506.	1.5	16
101	Natural killer cell functions mediated by the neuropeptide substance P. Regulatory Peptides, 2003, 116, 119-126.	1.9	67
102	Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology, 2003, 207, 85-93.	0.8	142
103	Expansion of Mobilized Peripheral Blood Progenitor Cells under Defined Culture Conditions Using CD34+CD71-CD45-Cells as a Starting Population. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 367-373.	1.8	3
104	Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation, 2003, 76, 435-436.	0.5	46
105	Evidence from a Leukemia Model for Maintenance of Vascular Endothelium by Bone-Marrow-Derived Endothelial Cells. Advances in Experimental Medicine and Biology, 2003, 522, 17-24.	0.8	32
106	Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research, 2003, 9, 606-12.	3.2	618
107	Bone Marrow-Derived Endothelial Cells for Therapeutic Angiogenesis and Antiangiogenesis: Facts and Visions. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 153-155.	1.8	1
108	High-Dose Hydroxyurea Plus G-CSF Mobilize BCR-ABL-Negative Progenitor Cells (CFC, LTC-IC) into the Blood of Newly Diagnosed CML Patients at Any Time of Hematopoietic Regeneration. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 293-300.	1.8	7

#	Article	IF	CITATIONS
109	Hematopoietic Angiogenesis. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 3-3.	1.8	Ο
110	In Vivo T Cell Depletion with Low-Dose Rabbit Antithymocyte Globulin Results in Low Transplant-Related Mortality and Low Relapse Incidence Following Unrelated Hematopoietic Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 731-737.	1.8	20
111	Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports. Blood, 2002, 99, 4632-4633.	0.6	7
112	Hepatosplenic γδ-T-cell lymphoma with leukemic course after renal transplantation. Human Pathology, 2002, 33, 253-258.	1.1	38
113	Blood levels of vascular endothelial growth factor in obstructive sleep apnea– hypopnea syndrome. Blood, 2002, 99, 393-394.	0.6	6
114	In vivo Release of Vascular Endothelial Growth Factor from Colorectal Carcinomas. Oncology, 2002, 62, 313-317.	0.9	15
115	Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. International Journal of Cancer, 2002, 98, 883-888.	2.3	89
116	Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes and Cancer, 2002, 34, 243-248.	1.5	31
117	Low concentrations of STI571 in the cerebrospinal fluid: a case report. British Journal of Haematology, 2002, 117, 623-625.	1.2	90
118	Circulating endothelial cells after transplantation. Lancet, The, 2001, 357, 1449.	6.3	17
119	Palliative Chemotherapy in Pretreated Patients with Advanced Cancer: Oral Trofosfamide Is Effective in Ovarian Carcinoma. Cancer Investigation, 2001, 19, 808-811.	0.6	19
120	Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. British Journal of Haematology, 2001, 113, 180-184.	1.2	94
121	Vascular Endothelial Growth Factor in Bacterial Meningitis: Detection in Cerebrospinal Fluid and Localization in Postmortem Brain. Journal of Infectious Diseases, 2001, 183, 149-153.	1.9	51
122	Receptor-Mediated Endocytosis of CD34 on Hematopoietic Cells after Stimulation with the Monoclonal Antibody Anti-HPCA-1. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 863-871.	1.8	5
123	Optimal Timing for the Collection and In Vitro Expansion of Cytotoxic CD56+ Lymphocytes from Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 513-521.	1.8	12
124	Contribution of Endothelial Cells of Hematopoietic Origin to Blood Vessel Formation. Circulation Research, 2001, 88, E1.	2.0	23
125	SERUMâ€,VASCULARâ€,ENDOTHELIALâ€,GROWTH FACTORâ€,ISâ€,ELEVATEDâ€,INâ€,CYSTICâ€,FIBROSIS ANDâ€,DECREASESâ€,WITHâ€,TREATMENTâ€,OF ACUTEâ€,PULMONARYâ€,EXACERBATION. American Journal o and Critical Care Medicine, 2001, 163, 1030-1031.	f R esp irat	ory4
126	Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-β1 in Serum of Patients With Acute Ischemic Stroke. Stroke, 2001, 32, 275-278.	1.0	40

#	Article	IF	CITATIONS
127	ANGIOGENIC GROWTH FACTORS AND ENDOSTATIN IN NON-HODGKIN'S LYMPHOMA. British Journal of Haematology, 2000, 108, 661-662.	1.2	1
128	Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19. Laboratory Investigation, 2000, 80, 1071-1077.	1.7	111
129	Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathologica, 2000, 100, 101-105.	3.9	70
130	Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood. Oncology, 2000, 58, 169-174.	0.9	161
131	Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet, The, 2000, 355, 1688-1691.	6.3	321
132	Space flight and growth factors. Lancet, The, 1999, 353, 1529.	6.3	7
133	Vascular endothelial growth factor platelet counts and renal cancer. Lancet, The, 1999, 353, 2247.	6.3	8
134	Angiogenesis as a Target for Tumor Treatment. Oncology, 1997, 54, 177-184.	0.9	99
135	Anticoagulant-induced Pseudothrombocytopenia and Pseudoleucocytosis. Thrombosis and Haemostasis, 1995, 73, 506-513.	1.8	75